Sandeep Nathan, MD, FSCAI Moderator
Frank J.Amico Jr., DOPharmacodynamics of Antiplatelet Therapies With and Without CS
Michele L Esposito, MD, FSCAI Case presentation
Srihari S. Naidu, MD, FSCAIOptimal Antiplatelet Strategies in High-Risk Patients
Jennifer A. Rymer, MD, MBA, MHS Data for use of Cangrelor in AMI-CS and High-Risk PCI
This activity is supported by an unrestricted educational grant from Chiesi.
Upon completion of this activity, participants will be able to:
Review current data on antiplatelet considerations in acute coronary syndrome and cardiogenic shock.
Describe contemporary antiplatelet treatment protocols in STEMI and cardiogenic shock.
Discuss future antiplatelet and antithrombotic therapeutic targets.
PLANNER
Sandeep Nathan: No financial relationships with ineligible companies.
FACULTY
Frank Amico, Michele Esposito, Srihari Naidu: No financialrelationships with ineligible companies.
Jennifer Rymer: Chiesi - PI.
REVIEWER
Benham Tehrani: No financial relationships with ineligible companies.
SCAI STAFF
Kristen Perry, Rachel Pham, and Laura Porter: No financial relationships with ineligible companies
Accreditation StatementThe Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit DesignationSCAI designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful CompletionWatch the content and complete the evaluation to obtain credit.Activity TimelineRecord date: September 19, 2025Publish date: December 1, 2025Retire date: December 1, 2028
As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.Planning Process SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.Mitigation of Relevant Financial RelationshipsAll participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins.
Content Validation StatementSCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.